Connect with us

Medicinal

MGC Pharma pressing ahead with clinical trials despite Covid-19 pandemic

The company is using funding raised via the London Stock Exchange to fund the studies

Published

on

Medical cannabis company MGC Pharma is pressing ahead with clinical trials despite ‘hurdles’ created by the pandemic.

The London Stock Exchange-listed firm MGC Pharma has reported updates on three separate trials planned for 2021.

Data collected from the trials will be used to advance the companies aim of ‘developing and supplying affordable standardised phytocannabinoid derived medicines’.

A phase two study into CannEpilÒ, an ‘add-on treatment’ for severe epilepsy, will take place at the Schindler Hospital and involve more than 100 patients.

Separately, 50 patients will be enrolled in trials CogniCannÒ via the University of Notre Dame in Perth, Western Australia to evaluate the potential behavioural benefits of the drug on patients with dementia and Alzheimer’s disease.

Studies into the effect of CimetrATM, a non-cannabis based natural inflammatory, on patients with Covid-19 are also progressing at two separate Israeli hospitals, with plans to expand the trial to Brazil.

According to a company statement, delays in the process have been ‘a result of logistical issues surrounding obtaining bulk supply of a key ingredient’ in the treatment due to the pandemic.

MGC Pharma raised £6.5m via its IPO on the LSE in February.

Roby Zomer, co-founder and managing director of MGC Pharma, said: “All of our clinical trials are progressing well despite the various hurdles we are facing due to the current global situation.

“These trials ensure MGC Pharma and our product offering realise their full medical and commercial potential as we focus on creating new and effective treatments for conditions and diseases that currently have no treatment options.”

Medicinal

AMP exclusive enters cannabis extract distribution agreement in Germany

The three-year agreement will see AMP become the exclusive distribution partner for Australia-based Little Green Pharma. 

Published

on

AMP exclusive enters cannabis extract distribution agreement in Germany

AMP Alternative Medical Products  (AMP) and Little Green Pharma (LGP) have entered into the partnership for the distribution of full-plant cannabis extract oils in Germany.

The company, a wholly-owned subsidiary of Greenrise Global Brands, has been appointed as marketer and distributor of LGP medical cannabis extracts to pharmacies and clinics in Germany. 

This will include LGP’s 20:5 LGP Classic and 10:10 LGP Classic extract oils in 30 and 50 milliliter sizes.

The news follows AMP’s announcement earlier this week that the company entered into a marketing and distribution agreement for the sale of Dronabinol in pharmacies with Eurox Pharma in the country.

Managing director of Little Green Pharma, Fleta Solomon, commented: “We set the strategic objective to be one of the leading medical cannabis extract producers and distributors in Europe, which means being a leader in Germany, the largest medical cannabis market in the world. 

“Our partnership with Greenrise Global’s daughter company, AMP Alternative Medical Products GmbH, puts us on course to that path.”

Dr Stefan Feuerstein, president and director of Greenrise Global and managing director of AMP, commented: ”We are seeing the industry mature with the growth of pharmaceutical cannabis products over flowers and are excited about adding LGP medical cannabis extracts to our portfolio.”

LGP was among the first medical cannabis companies to produce and export medical cannabis oils to Germany.

The company is also the primary medical cannabis extract oil supplier in France’s two-year medical cannabis trials being conducted by the French National Agency for the Safety of Medicines and Health Products.

Continue Reading

Medicinal

AMP Alternative Medical Products begins Dronabinol sales in Germany

The company is a medical cannabis subsidiary of Greenrise Global Brands.

Published

on

AMP Alternative Medical Products begins Dronabinol sales in Germany
Home » News » MGC Pharma pressing ahead with clinical trials despite Covid-19 pandemic

AMP Alternative Medical Products (AMP) and Eurox Pharma have begun the sales of Dronabinol produced in Germany by Eurox.

Greenrise Global subsidiary, AMP and Eurox, a SEED Innovations Limited portfolio company and one of Europe’s leading medical cannabis companies, entered into a non-exclusive marketing and distribution agreement for Dronabinol for sale in pharmacies to begin in February 2022. 

In preparation for sales, AMP has trained its national sales team on the benefits of Dronabinol – a pure THC product primarily used in pain therapy – for patients to doctors and preparation methods for pharmacists.

Chairman of Eurox, Neil Smith, commented: “If you’re a believer in the ‘Made in Germany’, then that means Eurox. 

“AMP’s focus on serving German patients and its national sales coverage make them a perfect partner for us.”

Eurox was one of the first medical cannabis companies to produce Dronabinol made in Germany at one of Europe’s largest GMP facilities located in Hessen, Germany.

The company controls the entire supply chain from cultivation, production to distribution ensuring a stable and efficient supply to its customers.

AMP is based in Erfurt and supplies medical cannabis products to pharmacies across Germany, including medical cannabis brands from Aphria, Bedrocan, Little Green Pharma and AMP’s branded line of products.

Eurox began the white label sale of its dronabinol products to a number of select customers in November 2021. Eurox selected Materia Deutschland, a wholly-owned subsidiary of European medical cannabis and CBD wellness products Materia, as as a distribution partner for its medical cannabis extracts.

Continue Reading

Medicinal

Agreement aims to approve first cannabis vaporiser for European patients

A collaboration will see studies undertaken to prove the efficacy and safety of the device.

Published

on

Agreement aims to approve first cannabis vaporiser for European patients

German-based Eurox Group has entered into an exclusive agreement with the US multi-state Orchid Ventures.

Under the agreement, Eurox, PurTec and JWEI, the company’s original equipment manufacturer (OEM) supplier and partner, will submit one of PurTec’s premium disposable vaporiser devices to authorities in Germany for Medical Device Approval. 

The agreement is PurTec’s first European project.

Read more: Eurox begins sale of cannabis products in Germany

Founder, CEO and chairman of Orchid, Corey Mangold, commented: “After months of planning and strategising, we are pleased to announce our partnership with such an established group in Eurox.

“We’re thrilled to join forces with Eurox and to be submitting one of our most stringently tested vaping products for Medical Device Approval with German health authorities. 

“Once the product is accepted, this will be a huge step forward in our ability to deliver one of the first vaping products to patients and consumers in Germany along with several other European countries. 

“We are confident that with the combined experience and expertise of Eurox and JWEI, we will succeed in getting approval and be among one of the first vaporiser products in-market and available to consumers throughout the EU.”

Read more: Materia enters agreement with Eurox for cannabis extract distribution

The companies will be working on several requirements and safety studies to prove the efficacy and safety of the device, and have already begun securing various certifications to speed up the approval process. 

If and when approval is given for the device Eurox will have exclusivity regarding sales and distribution of the PurTec product in the European Union, United Kingdom and Brazil.

Co-CEO of Eurox, Dr Bernhard Babel, commented: “We are excited about this partnership. 

“We believe that PurTec and JEWI will be valuable, long-term partners that can help us expand access to relevant and exciting new products that will compliment our portfolio and advance our growth trajectory. 

“Our objective is to deliver with liquid vaping a controlled and consistent therapy form to patients with need for inhaling in Europe and beyond.”

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts